Physician profile
Natalie Earl
NPI 1346289394
$13,659.84
in general payments reported to CMS, 2019-2025
19 companies · $8,451 in 2025
The $8,451 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $130 · 2021: $574 · 2022: $2,321 · 2023: $518 · 2024: $1,240 · 2025: $8,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,719 · Travel and Lodging: $3,065 · Honoraria: $2,000 · Consulting Fee: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.54 |
| Travel and Lodging | $3,065.17 |
| Honoraria | $2,000.00 |
| Consulting Fee | $1,425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $9,232.46 | 2019-2025 | Inspire |
| Aerin Medical INC. | $1,031.68 | 2024-2025 | |
| Glaxosmithkline, LLC. | $755.64 | 2021-2025 | Nucala |
| Optinose US, INC. | $740.20 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $684.68 | 2020-2025 | Dupixent |
| Genzyme Corporation | $659.21 | 2019-2025 | |
| Acclarent, INC | $178.24 | 2019-2021 | |
| Integra Lifesciences Corporation | $79.91 | 2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Merck Sharp & Dohme LLC | $43.66 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $39.08 | 2023-2024 | Ryaltris |
| Kaleo, INC. | $35.29 | 2021-2022 | |
| Harmony Biosciences LLC | $28.90 | 2025 | |
| Arbor Pharmaceuticals, INC. | $28.49 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.25 | 2025 | Voquezna |
| Csl Behring | $22.49 | 2025 | Andembry |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.17 | 2025 | Zepbound |
| Stryker Corporation | $18.80 | 2024 | Audion Et Dilation System |
| Smith+Nephew, INC. | $17.65 | 2019 | |
| Amgen INC. | $17.04 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.